MedPath

Clinical Trial News

Tryptamine Therapeutics Advances Clinical Trials, Sets Date for AGM

  • Tryptamine Therapeutics is progressing with its clinical trials, aiming to address unmet needs in mental health.
  • The company has scheduled its Annual General Meeting (AGM), signaling continued corporate governance activities.
  • These advancements reflect Tryptamine Therapeutics' ongoing efforts in pharmaceutical research and development.

Recreational Drug Use Triples Risk of Repeat Cardiovascular Events

  • A recent study presented at the European Society of Cardiology Congress 2024 reveals that recreational drug use triples the risk of repeat cardiovascular events within one year of hospitalization.
  • Cannabis was the most frequently detected substance (9.8%), followed by heroin and other opioids (2.3%), cocaine (1.7%), amphetamines (0.6%), and MDMA (0.6%).
  • Patients testing positive for recreational drugs had a significantly higher rate of major adverse cardiovascular and cerebrovascular events (MACCE) compared to non-users (13% vs. 6%).
  • The study suggests systematic screening for recreational drug use in intensive care settings could improve risk stratification and personalized care to support drug withdrawal.

Electroacupuncture Boosts Antiemetic Therapy for Chemotherapy-Induced Nausea

  • Electroacupuncture combined with standard antiemetic therapy significantly improves complete protection against chemotherapy-induced nausea and vomiting (CINV).
  • A randomized controlled trial showed a complete protection rate of 52.9% with true electroacupuncture versus 34.5% with sham electroacupuncture.
  • Patients receiving true electroacupuncture experienced enhanced total control and reduced significant nausea compared to the sham group.
  • Post-hoc analysis revealed that electroacupuncture significantly improved complete protection during the delayed phase of CINV.

Brentuximab Vedotin Triplet Shows Superior Outcomes in Relapsed/Refractory DLBCL

  • The ECHELON-3 study reveals that adding brentuximab vedotin to lenalidomide and rituximab significantly improves overall survival in relapsed/refractory DLBCL patients.
  • The triplet therapy reduces the risk of disease progression or death by 47% compared to lenalidomide and rituximab alone, demonstrating a substantial PFS benefit.
  • The objective response rate with the brentuximab vedotin triplet was 64.3%, significantly higher than the 41.5% achieved with the doublet.
  • No new safety concerns arose with the addition of brentuximab vedotin, and adverse events were manageable with dose modifications.

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283Active, Not RecruitingPhase 3
Seagen, a wholly owned subsidiary of Pfizer
Posted 8/20/2020

AI-Powered MRI Analysis Predicts Breast Cancer Outcomes and Treatment Response

  • A new AI model uses radio-multiomic analysis of breast cancer MRI scans to predict relapse-free survival and overall survival, enhancing prognosis accuracy.
  • The model integrates radiomic features with multiomic data, including genomics and metabolomics, to reveal biological underpinnings of tumor behavior.
  • This AI tool can also predict patient response to neoadjuvant chemotherapy, potentially guiding personalized treatment decisions.
  • Validation across multiple independent cohorts (FUSCC, DUKE, I-SPY1) demonstrates the robustness and generalizability of the AI-driven approach.

Clinical Study of Imaging Genomics Based on Machine Learning for BCIG

NCT04461990Unknown Status
Fudan University
Posted 12/1/2020

Unicycive Therapeutics' OLC for Hyperphosphatemia Receives 'Buy' Rating Amidst NDA Submission

  • Unicycive Therapeutics' Oxylanthanum Carbonate (OLC) NDA submission for hyperphosphatemia treatment in chronic kidney disease patients on dialysis has garnered a 'Buy' rating.
  • The FDA waived PDUFA fees for OLC, presenting a cost-saving benefit, and studies suggest favorable tolerability and efficacy in phosphate control.
  • Analysts anticipate the approval of OLC could unlock a significant revenue opportunity, supported by the company's sound financial position and potential dividend payouts.
  • Despite a reduced 12-month price target due to TDAPA uncertainties, analysts maintain a positive outlook, expecting resolution and OLC approval.

Immunic's IMU-838 Enters Phase 2 Trial for Post-COVID Syndrome

  • Immunic's IMU-838, an oral DHODH inhibitor, has advanced into a Phase 2 clinical trial targeting post-COVID syndrome, also known as long COVID.
  • The trial aims to evaluate IMU-838's efficacy in alleviating symptoms and improving the quality of life for individuals suffering from persistent post-COVID conditions.
  • IMU-838's mechanism of action involves inhibiting dihydroorotate dehydrogenase (DHODH), a key enzyme in pyrimidine synthesis, potentially modulating the immune response.
  • The Phase 2 trial represents a significant step in addressing the unmet medical need for effective treatments for post-COVID syndrome, which affects a substantial portion of individuals post-acute infection.

Global Survey Reveals Persistent Barriers to Lung Cancer Biomarker Testing Despite Growing Recognition

  • A 2024 global survey by IASLC shows significant improvement in biomarker testing rates for lung cancer patients, rising from 39% to 67% since 2018, though critical barriers remain.
  • Cost remains the primary obstacle at 27.2%, followed by time constraints (13.9%), tissue sample quality (13.8%), and access issues (12.8%), affecting both early- and late-stage lung cancer testing.
  • Despite 98.3% of healthcare providers acknowledging biomarker testing's impact on outcomes, 43% report treating patients before receiving test results, highlighting ongoing implementation challenges.

Golcadomide Plus R-CHOP Shows Promise in Aggressive B-Cell Lymphoma

  • Golcadomide combined with R-CHOP demonstrates a manageable safety profile and promising antitumor activity in previously untreated aggressive B-cell lymphoma.
  • The 0.4-mg dose of golcadomide with R-CHOP resulted in high complete metabolic response rates, irrespective of cell of origin, in the phase 1b CC-220-DLBCL-001 trial.
  • High-risk patients treated with the golcadomide combination showed encouraging 12-month progression-free survival and overall survival rates.
  • These findings support the ongoing phase 3 GOLSEEK-1 trial evaluating golcadomide plus R-CHOP versus R-CHOP alone in high-risk large B-cell lymphoma.

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129RecruitingPhase 3
Celgene
Posted 6/19/2024

India Approves Shorter, More Effective BPaLM Regimen for Drug-Resistant TB

  • India's Health Ministry has approved the BPaLM regimen for Multi-Drug-Resistant Tuberculosis (MDR-TB) treatment, offering a shorter, more effective option.
  • The BPaLM regimen, consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin, has demonstrated higher success rates over a six-month treatment period.
  • Pretomanid, a key drug in the BPaLM combination, has been licensed for use in India by the Central Drugs Standard Control Organization (CDSCO).
  • The initiative aligns with India's goal to eliminate TB by 2025, ahead of the global Sustainable Development Goal (SDG) target.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.